ZA959846B - Enzyme prodrug therapy - Google Patents

Enzyme prodrug therapy

Info

Publication number
ZA959846B
ZA959846B ZA959846A ZA959846A ZA959846B ZA 959846 B ZA959846 B ZA 959846B ZA 959846 A ZA959846 A ZA 959846A ZA 959846 A ZA959846 A ZA 959846A ZA 959846 B ZA959846 B ZA 959846B
Authority
ZA
South Africa
Prior art keywords
prodrug therapy
enzyme prodrug
enzyme
therapy
prodrug
Prior art date
Application number
ZA959846A
Inventor
Inderjit Kumar Dev
John Tomlin Moore
Carol-Ann Ohmstede
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA959846B publication Critical patent/ZA959846B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/84—Penicillin amidase (3.5.1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
ZA959846A 1994-11-18 1995-11-20 Enzyme prodrug therapy ZA959846B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423367A GB9423367D0 (en) 1994-11-18 1994-11-18 Enzyme prodrug therapy

Publications (1)

Publication Number Publication Date
ZA959846B true ZA959846B (en) 1997-05-20

Family

ID=10764658

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA959846A ZA959846B (en) 1994-11-18 1995-11-20 Enzyme prodrug therapy

Country Status (7)

Country Link
EP (1) EP0792366A1 (en)
JP (1) JPH10509326A (en)
AU (1) AU695375B2 (en)
CA (1) CA2205593A1 (en)
GB (1) GB9423367D0 (en)
WO (1) WO1996016179A1 (en)
ZA (1) ZA959846B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
GB9415167D0 (en) * 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9523703D0 (en) * 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO1999033870A2 (en) * 1997-12-31 1999-07-08 Incyte Pharmaceuticals, Inc. Human regulatory proteins
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
WO2001093826A1 (en) * 2000-06-06 2001-12-13 Sumitomo Pharmaceuticals Company, Limited Biocompatible synthetic polymer preparations
EP1364028A2 (en) * 2000-12-26 2003-11-26 Bayer Aktiengesellschaft Regulation of human carboxypeptidase a
ATE503838T1 (en) * 2003-10-28 2011-04-15 Friesland Brands Bv SITE-SPECIFIC ADMINISTRATION OF ACTIVE SUBSTANCES IN THE INTESTINAL

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135403T1 (en) * 1987-03-10 1996-03-15 New England Biolabs Inc PREPARATION AND PURIFICATION OF A PROTEIN FUSIONED WITH A BINDING PROTEIN
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
JPH05502880A (en) * 1989-12-22 1993-05-20 セラジェン・インコーポレーテッド Hybrid molecule with a translocation region and a cell binding region
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
US5342762A (en) * 1991-01-03 1994-08-30 Wisconsin Alumni Research Foundation Fibronectin purification vector
WO1994001567A1 (en) * 1992-07-08 1994-01-20 Unilever N.V. Process for immobilizing enzymes to the cell wall of a microbial cell by producing a fusion protein

Also Published As

Publication number Publication date
CA2205593A1 (en) 1996-05-30
EP0792366A1 (en) 1997-09-03
AU3877395A (en) 1996-06-17
JPH10509326A (en) 1998-09-14
AU695375B2 (en) 1998-08-13
WO1996016179A1 (en) 1996-05-30
GB9423367D0 (en) 1995-01-11

Similar Documents

Publication Publication Date Title
EG24678A (en) Combination therapy
GB9622500D0 (en) Therapeutic gene
AP2002002661A0 (en) Combination therapy for oesteoporosis
GB9421709D0 (en) Therapeutic compounds
CY2249B1 (en) Therapeutic compounds
IL127306A0 (en) Combination therapy
ZA9533B (en) Pentolifylline therapy
AU5252598A (en) Multi-trauma therapeutic machine
GB9523703D0 (en) Enzyme prodrug thearapy
GB9700939D0 (en) Therapy
GB9423367D0 (en) Enzyme prodrug therapy
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
GB9407484D0 (en) Enzyme
GB9422157D0 (en) Enzyme
GB9523714D0 (en) Enzyme prodrug therapy
ZA977005B (en) Therapeutic uses
GB9418696D0 (en) Gene therapy
GB9402573D0 (en) Phosphatases
GB2333527B (en) Therapeutic gene
GB9605466D0 (en) Therapy
GB9605525D0 (en) Therapy
GB9704885D0 (en) Therapy
GB9409030D0 (en) Enzyme
GB9505272D0 (en) Combination therapy
AU2003200183A1 (en) Cholestrol-lowering Therapy